• Active, not recruiting

NCT01190787: Phase 2: EMN - Velcade/Melphalan/Pred or Velcade/Cycloposphamide/Pred or Velcade/Pred.

Updated: Sep 25

EMN - European Myeloma Network

Subcutaneous Velcade Plus Oral Melphalan and Prednisone or Plus Cycloposphamide and Prednisone or Plus Prednisone

emn

This protocol is a single-arm, three-cohort, phase II multicenter study designed to assess the safety and the efficacy of three all-oral combinations: Velcade with continuous low-dose melphalan and prednisone (VMP) or with continuous low-dose cyclophosphamide and prednisone (VCP) or Velcade with low-dose prednisone could be effective and well tolerated (VP).


Sponsor

European Myeloma Network


Collaborator

Fondazione EMN Italy Onlus

 

ClinicalTrials.gov Identifier: NCT01190787

Official Title: A Multicenter Phase II Study of Subcutaneous Velcade Plus Oral Melphalan and Prdnisone or Plus Cycloposphamide and Prednisone or Plus Prednisone in Newly Diagnosed Elderly Multiple Myeloma Patients

First Posted : August 30, 2010

Click here for details on ClinicalTrials.gov

 

Drug: velcade subcutaneous melphalan prednisone

Drug: velcade cyclophosphamide prednisone

Drug: velcade prednisone

 

Haematologica; 2020

Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs

https://pubmed.ncbi.nlm.nih.gov/31221778/

 

Blood; 2015

Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report

https://pubmed.ncbi.nlm.nih.gov/25628469/

Click here to read details


MYELOMA FRAILTY SCORE CALCULATOR

http://www.myelomafrailtyscorecalculator.net/

 

Locations

Italy





Posts Archive